Navigation Links
Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference
Date:1/15/2014

PHILADELPHIA, Jan. 15, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, will present at "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference.

Mr. Doman will make a corporate presentation to prospective corporate partners and investors at 9:00 AM EST on Wednesday, January 22nd.  The Company's presentation will be delivered in Sandpiper Bay, Florida.

At the time of the presentation, a live audio and high-definition video webcast of Mr. Doman's presentation and a copy of the presentation materials will be available in the Events section of the Company's website at www.echotx.com, or through the Noble Financial websites: www.noblefcm.com or www.nobleresearch.com/TEN/2014.htm.  Echo recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access.  You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate.  The webcast and presentation will also be archived on www.echotx.com for 90 days following the event. 

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting, as well as i
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... Novartis, ranibizumab was approved by CFDA to treat wet ... Lucentis, a product of Novartis, is available in the ... self- developed drug for the treatment of wet AMD ...
(Date:8/28/2015)... Aug. 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... completed the acquisition of leading OTC brands from GSK ... The transaction is a clear demonstration of Perrigo,s unique ... European distribution network spanning 36 countries.  ... commented, "We are excited to complete this transaction, ...
(Date:8/28/2015)... , August 28, 2015 The ... Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ( ... Asia-Pacific , and Rest of the World) ... The global market for Eubiotics was valued at USD 4.62 ... Billion by 2020, at a CAGR of 7.4% from 2015 ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... 2 clinical study of NKTR-102 in patients with metastatic ... Cancer Symposium in San Francisco, California.  NKTR-102 is a ... conjugate technology, and is being developed in multiple tumor ...
... The Board of the European Fine Chemicals ... to ratify the proposal of the US Food and Drug ... the help of EFCG and US industry representatives, to deliver ... (GDUFA). GDUFA requires the FDA to commit to ...
Cached Medicine Technology:Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 2Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 3Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 4Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 5Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 6European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in the City, ... added yet another accolade to its cadre of widespread support—an official letter of support ... help of the medical community and the University of Illinois at Chicago’s Department of ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was featured on NewsWatch ... coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the host ... this software allows businesses to track product movement from beginning to end. , Businesses ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business ... veterans leading in business. Mr. Troy Mizell, Chairman of the Board at ... Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, through their ...
(Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ... by the Food and Drug Administration to eliminate submental fat, also known as the ... are among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... for those seeking to go deep sea diving. The act of recreational ... decompression sickness; for these reasons, it is vital that all recreational and professional ...
Breaking Medicine News(10 mins):Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Healthpointe Now Offering Scuba Physicals 2
... Vancouver Career College ... ... Career College in Surrey are digging through their closets to find clothing to. Now they’re ... need., , , , ,“Every day we focus on building a community here on campus ...
... Research Hospital and the University of Florida Proton Therapy Institute ... Jude patients. The announcement follows the approval of the first ... rare brain cancers in children younger than 3 years old. ... refer patients to receive proton therapy at the UF Proton ...
... Bright Horizons Family Solutions® today announced that it ... by the Boston Globe. The prestigious ranking on the Globe ... has always worked to support its employees and despite the ... on fostering a culture where employees feel valued and supported at ...
... computerized alerts can help curb the impulse to ... in the August issue of Journal of ... received computerized alerts, which compared medication brands, they ... marketed sleep medications to comparable generic equivalents. ...
... of those hurt are under 16, researchers say , MONDAY, ... the United States in recent years, rising by 160 percent ... , However, the total number of injuries related to hot ... remains fairly small at about 6,600 per year. , ...
... today the acquisition of App Tech Global, Inc., which will ... Nutrition,s name will be changed to App Tech, Corp. and ... App Tech Global, Inc. , App Tech is developing mobile ... App Tech is focused on multi platform apps designed to ...
Cached Medicine News:Health News:Surrey College Students Collect Clothing for Women and Children 2Health News:St. Jude Children's Research Hospital and UF Proton Therapy Institute to Begin Proton Therapy Clinical Trial 2Health News:St. Jude Children's Research Hospital and UF Proton Therapy Institute to Begin Proton Therapy Clinical Trial 3Health News:St. Jude Children's Research Hospital and UF Proton Therapy Institute to Begin Proton Therapy Clinical Trial 4Health News:Bright Horizons Named One of Boston Globe 100's Top Places to Work 2Health News:Computerized support keeps prominence of name brand drugs at bay 2Health News:Hot-Tub Injuries on the Rise 2
... We offer a complete ... bringing laboratorians state-of-the-art monoclonal and ... the detection of enteric pathogens ... includes products for Clostridium difficile, ...
... is a second-generation rapid ELISA for the detection ... fecal specimens. The test utilizes highly specific antibodies ... the more common toxin A+ samples, but also ... perform, produces no indeterminates and provides results in ...
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
Medicine Products: